A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 10 (1), 342-355
- https://doi.org/10.1080/22221751.2021.1887767
Abstract
The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. The novel combination of a DNA vaccine encoding the full-length Spike (S) protein of SARS-CoV-2 and a recombinant S1 protein vaccine induced high level neutralizing antibody and T cell immune responses in both small and large animal models. More significantly, the co-delivery of DNA and protein components at the same time elicited full protection against intratracheal challenge of SARS-CoV-2 viruses in immunized rhesus macaques. As both DNA and protein vaccines have been proven safe in previous human studies, and DNA vaccines are capable of eliciting germinal center B cell development, which is critical for high-affinity memory B cell responses, the DNA and protein co-delivery vaccine approach has great potential to serve as a safe and effective approach to develop COVID-19 vaccines that provide long-term protection.Funding Information
- Major Science and Technology Projects of Yunnan Province (2019ZF001, 202003AC100003, 202003AF140002)
- CAMS Initiative for Innovative Medicine (2016-I2M-1-019)
- Fundamental Research Funds for the Central Universities (2020HY320001)
This publication has 58 references indexed in Scilit:
- DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trialsThe Lancet Infectious Diseases, 2011
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Influenza H5 Hemagglutinin DNA Primes the Antibody Response Elicited by the Live Attenuated Influenza A/Vietnam/1203/2004 Vaccine in FerretsPLOS ONE, 2011
- Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidityVaccine, 2010
- Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against choleraVaccine, 2009
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza virusesVaccine, 2008
- Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA VaccinesJournal of Virology, 2006
- Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccineVaccine, 2006
- Identification of Two Neutralizing Regions on the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Produced from the Mammalian Expression SystemJournal of Virology, 2005